HLA phenotypes of candidates for HSCT: comparing transplanted versus non-transplanted candidates, resulting in the predictive estimation of the probability to find a 10/10 HLA matched donor

Tissue Antigens
P A GourraudF Garnier

Abstract

In order to study the impact of human leucocyte antigen (HLA) polymorphism distribution in identifying a matched haematopoietic stem cells unrelated donor (UD), we performed a multi-centric retrospective analysis with the aim of comparing the HLA-A, HLA-B, HLA-C, HLA-DRB1 and HLA-DQB1 phenotypes of 2126 patients (772 patients for whom a donor search failed to identify a matched UD, and 1354 patients who received a 10/10 allele level matched UD). Our results showed that rare HLA-C is often responsible for difficulty in identifying a donor. This locus may add a degree of complexity to a supposed 'frequent' HLA-A HLA-B and HLA-DRB1 phenotype, turning this phenotype into a less frequent one. For example, 32.5% of the phenotypes in the non-transplanted patients could not be explained by any of the pairs of known HLA-A, HLA-B, HLA-C and HLA-DRB1 haplotypes while this percentage dropped to less than 2% if combinations of only HLA-A, HLA-B and HLA-DRB1 haplotypes were considered. Such situations can be anticipated by computing an index, based on HLA haplotype frequency, the average registry sample size (ARS). ARS is defined as the inverse of the phenotype frequency computed using all corresponding pairs of haplotype frequencies. ARS co...Continue Reading

References

Jan 1, 1997·Human Immunology·R F SchipperM Oudshoorn
Aug 26, 1998·Human Immunology·R F SchipperM Oudshoorn
Oct 2, 1998·Tissue Antigens·S RendineE S Curtoni
Jul 15, 2004·European Journal of Human Genetics : EJHG·Pierre-Antoine GourraudAnne Cambon-Thomsen
Sep 16, 2004·Genetic Epidemiology·Tianhua Niu
Jun 7, 2005·Human Immunology·Pierre-Antoine GourraudAnne Cambon-Thomsen
Mar 24, 2007·PLoS Medicine·Effie W PetersdorfZhen Guo
Jul 21, 2007·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Pascale LoiseauColette Raffoux
Sep 18, 2007·Human Immunology·Martin MaiersWilliam Klitz
May 27, 2009·Briefings in Functional Genomics & Proteomics·Claire Vandiedonck, Julian C Knight
Oct 23, 2009·Tissue Antigens·W KlitzC K Hurley
Dec 5, 2009·Best Practice & Research. Clinical Haematology·Mary M Horowitz

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.